Alta Life Sciences leads an oversubscribed investment round into Inbiomotion to launch its diagnostic product in breast cancer

• The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing. • Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis. • The capital increase is intended to complete regulatory…

Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists

Five neurology experts join CNS specialist’s scientific advisory board to support clinical trial development of disease modifying drug candidates  Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of five world-class neurology experts to its scientific advisory board. They will help boost innovation and advocate for Accure Therapeutics, as the company drives…

Peptomyc announces a new equity financing round of 11.4M€

This investment will help Peptomyc lead its drug candidate OMO103 into clinical phase I/II as a treatment for solid tumors Barcelona, Spain, December 15, 2020 – Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics for cancer treatment, has just announced the completion of an equity financing round of EUR 11.4 million. The company is focused on the development of a new generation of cell penetrating…